ZA966954B - Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation. - Google Patents

Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.

Info

Publication number
ZA966954B
ZA966954B ZA9606954A ZA966954A ZA966954B ZA 966954 B ZA966954 B ZA 966954B ZA 9606954 A ZA9606954 A ZA 9606954A ZA 966954 A ZA966954 A ZA 966954A ZA 966954 B ZA966954 B ZA 966954B
Authority
ZA
South Africa
Prior art keywords
prevention
polytrauma
blood circulation
extracorporeal blood
selectin antibodies
Prior art date
Application number
ZA9606954A
Other languages
English (en)
Original Assignee
Protein Designs Labs Inc
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Designs Labs Inc, Boehringer Mannheim Gmbh filed Critical Protein Designs Labs Inc
Publication of ZA966954B publication Critical patent/ZA966954B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
ZA9606954A 1995-08-17 1996-08-16 Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation. ZA966954B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95112895 1995-08-17
EP95114696 1995-09-19
US57895395A 1995-12-27 1995-12-27

Publications (1)

Publication Number Publication Date
ZA966954B true ZA966954B (en) 1998-02-16

Family

ID=27236574

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606954A ZA966954B (en) 1995-08-17 1996-08-16 Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.

Country Status (11)

Country Link
EP (1) EP0868197B1 (no)
JP (1) JP3604699B2 (no)
AT (1) ATE265861T1 (no)
AU (1) AU6773596A (no)
CA (1) CA2229140A1 (no)
CZ (1) CZ45498A3 (no)
DE (1) DE69632407T2 (no)
HU (1) HUP9901673A3 (no)
PL (1) PL187090B1 (no)
WO (1) WO1997006822A1 (no)
ZA (1) ZA966954B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
CN102924598B (zh) 2002-03-13 2014-12-31 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
BRPI0714381A2 (pt) 2006-07-10 2013-03-05 Biogen Idec Inc composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508991A (ja) * 1991-06-25 1994-10-13 ダナーファーバー　キャンサー　インスティチュート リンパ細胞に結合した表面タンパク質に対するモノクローナル抗体
AU2410292A (en) * 1991-07-29 1993-03-02 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to leukocyte adhesion molecule-1
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
WO1995015181A1 (en) * 1993-11-30 1995-06-08 Protein Design Labs, Inc. Reperfusion therapy using antibodies to l-selectin

Also Published As

Publication number Publication date
CA2229140A1 (en) 1997-02-27
DE69632407T2 (de) 2005-06-02
DE69632407D1 (de) 2004-06-09
PL187090B1 (pl) 2004-05-31
EP0868197A4 (no) 1998-11-18
AU6773596A (en) 1997-03-12
PL325012A1 (en) 1998-07-06
HUP9901673A3 (en) 2001-06-28
JPH10510553A (ja) 1998-10-13
JP3604699B2 (ja) 2004-12-22
HUP9901673A2 (hu) 1999-08-30
EP0868197B1 (en) 2004-05-06
ATE265861T1 (de) 2004-05-15
EP0868197A1 (en) 1998-10-07
CZ45498A3 (cs) 1999-01-13
WO1997006822A1 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
AU594488B2 (en) Agents for the treatment of arthroses
AU3070897A (en) Global financial services integration system and process
AU1690497A (en) Automatic well test system and method of operating the same
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
AU5794996A (en) Gaming table, tracking system and method
EP0918529A4 (en) GRAFTS MANUFACTURED FROM AMNIOTIC MEMBRANES, METHODS OF SEPARATING, PRESERVING AND USING SUCH GRAFTS IN SURGERY
HK1029859A1 (en) Voice recognizing and translating system.
EP0652512A3 (en) Method and system for managing component connections.
WO1998025597A3 (en) Method for treating and preventing heart failure and ventricular dilatation
EP0487627A4 (en) Wound healing preparations containing heparanase
TR199501643A2 (tr) Yünün enzimlerle tedavisi icin yöntem.
DE69719775D1 (en) Thrombin inhibitoren
NO975557L (no) Immortalisering og dissimortalisering av celler
ZA966954B (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.
AU7150294A (en) Method and system of collecting, processing and storing blood components
AU7816694A (en) Method and system for the treatment of seeds and bulbs
DE69523296D1 (de) Molkeprotein/polysaccharide Gel, hergestellt durch Hochdruckbehandlung
EP0663218A3 (en) Method and system of cardiac stimulation in VDD (R) mode.
EP0858262A4 (en) THROMBIN INHIBITORS
NO974811D0 (no) CNS-utvekstmodulatorer, preparater, celler og fremgangsmåter som omfatter og anvender slike
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
ATE215084T1 (de) Imidazopyridin-azolidinone
TW336890B (en) Method of making more than one punchout from a single dried blood spot
NO881414L (no) Fremgangsmaate for behandling av spillvann og annet urent vann.